- Retinitis pigmentosa (RP) is a group of rare, inherited eye disorders that involve a breakdown and loss of cells in the retina, ultimately leading to progressive vision loss. The market for RP treatment is expanding rapidly due to innovations in therapeutic strategies such as gene therapy, retinal implants, stem cell therapy, and vitamin supplementation
- A significant driver for this market is the growing investment in genetic testing and personalized medicine, which is enabling earlier diagnosis and more targeted treatment approaches. The increasing availability of advanced diagnostic tools like electroretinograms and genetic screening is further enhancing disease management and prognosis
- North America currently holds the largest share of the global retinitis pigmentosa treatment market, accounting for 38.2%, owing to a well-established healthcare infrastructure, strong presence of leading biotech firms, favorable reimbursement policies, and a high rate of adoption of novel therapies such as Luxturna (voretigene neparvovec)
- Asia-Pacific is projected to witness the fastest growth in the global retinitis pigmentosa treatment market throughout the forecast period, driven by increasing awareness campaigns, improvement in genetic testing capabilities, and the growing number of patients opting for treatment in emerging economies like China and India
- The autosomal recessive segment is projected to hold the largest share in 2025, driven by its higher prevalence among RP cases globally. Autosomal recessive RP accounts for a significant portion of diagnosed cases due to the inheritance pattern involving both parents. This form often presents early in life and tends to be more severe, resulting in a greater need for early diagnosis and intervention. Ongoing genetic screening initiatives and rising awareness of hereditary eye disorders are contributing to the increased detection of autosomal recessive RP, further propelling the growth of this segment.
